CagriSema vs Semaglutide in Type 2 Diabetes Paramesh Shamanna posted on the topic LinkedIn The next frontier in metabolic health: Cagrilintide Semaglutide and the evolving landscape of therapies Semaglutide, a glucagon like peptide 1 (GLP 1) receptor agonist, has well established weight loss benefits. Cagrilintide, a long acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential benefit Comparative Efficacy and Safety of Semaglutide, Cagrilintide, and CagriSema for the Treatment of Type 2 Diabetes Mellitus: A Bayesian Network Meta Analysis Journal of Clinical Question Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 24 mg for weight management: a randomised, controlled, phase 1b trial The Lancet Cagrilintide 3mg, Semaglutide 3mg Blend (SALE!) Polaris Peptides